CD8A and small cell lung carcinoma: CheckMate 032 revealed that patients with SCLC with CD8-positive (≥1%) tumors showed improved OS (HR, 0.51) in the Nivolumab group, and a similar trend was observed in the Nivolumab + Ipilimumab group (HR, 0.7; 95% CI) (48).